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Serum immune complexes in membranoproliferative and other
glomerulonephritides. Immune complexes were detected in the se-
rum of patients with membranoproliferative glomerulonephritis
(MPGN) Types I and II, systemic lupus erythematosus (SLE), and
acute poststreptococcal glomerulonephritis (AGN) by sucrose
gradient ultracentrifugation and by measurement of Clq binding
activity (Clq-BA). Clq-BA was more sensitive in detecting com-
plexes than was gradient ultracentrifugation. By gradient ultra-
centrifugation, the sedimentation velocities of the complexes in the
three diseases were similar, ranging from 13S to 19S. This range
corresponds to that observed by others in experimental chronic
serum sickness nephritis. The complexes isolated by gradient ultra-
centrifugation always contained C3, usually IgG and C4, and, in
some patients with SLE and AGN, 1gM. In MPGN, 1gM and IgA
could be present in glomerular deposits when not present in circu-
lating complexes. In this disease also, serum complement levels
were poor predictors of the presence of complexes. With increased
Clq-BA, the levels of Clq, C4, and C2 could be normal or reduced
and there was no correlation with C3 levels. With few exceptions,
the clinical status of the patients with MPGN correlated well with
Clq-BA.
Complexes immuns sériques dans les glomerulonephrites mem-
brano-prolifératives et d'autres types. Des complexes immuns ont
été détectés dans le serum de malades atteints de MPGN des types
I et 11, de SLE, et d'AGN par ultracentrifugation en gradient de
sucrose et par Ia mesure de l'activité de liaison du Clq (Clq-BA).
La mesure de Clq-BA est plus sensible pour Ia detection des
complexes que l'ultracentrifugation en gradient de densité. Avec
cette dernière méthode les vitesses de sedimentation des complexes
sont similaires dans les trois affections, allant de 13 S a 19 S. Cet
éventail de valeurs correspond a ce qui a été observe par d'autres
dans Ia néphrite de Ia maladie chronique du serum. Les complexes
isolés par ultracentrifugation en gradient contiennent toujours du
C3, habituellement de l'lgG et du C4 et, chez quelques malades
atteints de SLE et d'AGN, de l'IgM. Dans Ia MPGN l'IgM et
l'IgA peuvent être déposées dans les glomérules bien qu'elles
n'existent pas dans les complexes immuns. Dans cette maladie les
concentrations sériques de complement ne permettent pas de pré-
voir avec sécurité Ia presence de complexes. Quand Clq-BA est
augmenté les concentrations de Clq, C4, et C2 peuvent être nor-
males ou diminuées et il n'y a pas de correlation avec Ia concentra-
tion de C3. A quelques exceptions près l'état clinique des malades
atteints de MPGN est bien corrélé avec Clq-BA.
Analyses of cryoprecipitates and measurements of
Clq binding have given direct and indirect evidence of
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the presence of circulating immune complexes in the
serum of patients with the nephritis of systemic lupus
erythematosus (SLE) [1—4] and of chronic bactere-
mia [5]. Studies designed to isolate or to characterize
Clq binding complexes in the serum of patients with
membranoproliferative glomerulonephritis (M PGN)
or with acute poststreptococcal glomerulonephritis
(AGN) have not been previously reported, but com-
plexes have been detected in MPGN by inhibition of
uptake of aggregated IgG by guinea pig peritoneal
macrophages [6]. In the present study, complexes
binding radiolabeled CIq have been detected in the
serum of patients with MPGN by means of sucrose
density gradient ultracentrifugation, and their immu-
noglobulin and complement composition and their
sedimentation velocity have been compared with
those of complexes found in the serum of patients
with AGN and SLE. In addition, the results of
gradient ultracentrifugation have been correlated
with the Clq binding activity (Clq-BA) of the serum
as measured by the amount of 125 I—Clq precipitated
by 2.5% polyethylene glycol (PEG) [3]. For the
patients with MPGN, the results have also been cor-
related with the clinical course, with the glomerular
immunohistology, and with the complement profile.
Methods
The study was performed on serum specimens
from 20 patients with MPGN, 21 with SLE, 20 with
AGN, and 44 normal subjects. The patients with
MPGN were divided into two groups according to
the location of the glomerular deposits, as deter-
mined by electron microscopy. Ten had sub-
endothelial and mesangial deposits and were desig-
nated Type I, and ten had intramembranous dense
deposits as well as mesangial deposits and were desig-
nated Type II. The serum specimens from four of the
patients with Type II disease were obtained after they
had undergone renal transplantation, and two of
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these had clinical evidence of recurrence of the dis-
ease in the transplanted kidney. None of the serum
specimens from the patients with MPGN had detect-
able C3 nephritic factor activity.
The patients with AGN were all children who had
a transient glomerulonephritis characterized by
hematuria and proteinuria, hypocomplementemia,
and had either a history of an antecedent illness com-
patible with streptococcal infection or had elevation
of the titer of antibodies to streptococcal enzymes.
Those with SLE had renal disease typical, clinically
and morphologically, of this disorder, and antinu-
clear antibody was present in the serum.
Blood was allowed to clot at room temperature
and the serum removed after centrifugation. The
blood was used fresh or after storage at —70°C.
Isolation and labeling of Clq: Clq was purified from
human serum by the method of Yonemasu and
Stroud [7]. The purity of the preparation was estab-
lished by the demonstration of a single precipitin line
on double immunodiffusion against a highly poly-
valent antiserum to whole human serum. There was
no evidence of contamination with IgG, IgA, or 1gM
by radial immunodiffusion using a monospecific an-
tibody to these proteins. The isolated protein was
labeled with 125 I according to a modified lactoperoxi-
dase technique [8]. After labeling, the solution was
dialyzed against several changes of veronal buffered
saline (VBS) to remove free iodine. After dialysis, the
specific radioactivity was 0.08 to 0.2Ci/g of Clq.
The labeled material produced a single peak of radio-
activity by cellulose acetate electrophoretic analysis
and by sucrose density gradient analysis.
The 125 I-Clq was stored in 0.2-ml aliquots at
--70°C until used. Immediately before use, the prepa-
ration was rapidly thawed in a 37°C water bath and
centrifuged at X25,000 g for 30 mm to remove aggre-
gates.
Measurement of Clq-BA: The conditions for the
complexing of radiolabeled Clq to serum complexes
were essentially as described by Nydegger and asso-
ciates [3], with slight modification. Prior to use, the
serum to be analyzed was heated to 56°C for 30 mm
and immediately cooled in an ice bath. To 0.1 ml of
the heated test serum was added 0.1 ml of VBS, pH
7.4, containing 0.005 M veronal and 0.1 M NaCl,
followed by 100 ng of 125 I-Clq. This mixture was
incubated at room temperature for one hour and then
at 4°C in an ice bath for one hour, At the end of this
incubation, PEG (average mol wt, 6000) was added to
a final volume of 2 ml in a final concentration of
2.5%. Incubation was at 4°C for another two hours.
The tubes were then centrifuged at X2000 g for 20
mm. The upper half of the supernatant (s) was care-
fully pipetted off of each tube so that one half of the
supernatant plus precipitate (r) remained in the tube.
The radioactivity was counted in the S and r frac-
tions. Clq-BA was calculated as percent of 125 I-Clq
precipitated according to the formula r — s/r + s X
100. Serum specimens from five normal subjects were
included in each test run.
Detection of immune complexes by sucrose density
gradient analysis. Serum samples were heat-treated at
56°C for 30 mm, VBS and '251-Clq were added, and the
mixture was incubated at room temperature and at
4°C, as for the measurement of Clq binding activity de-
scribed above. At the end of this incubation, 0.2 ml of
the mixture was subjected to sucrose density gradient
analysis [2, 91, and the sedimentation coefficient of the
complexes was calculated [10] from the position of
the peak of radioactivity in the heavily sedimenting
region representing the Clq bound complex. A serum
specimen from a normal subject was included as a
control in each analysis of the patient's serum. The
ability of preparations of 125 I-Clq to bind to com-
plexes was tested prior to use by analysis, by the
above procedure, of normal serum to which had been
added small amounts of human IgG-anti IgG com-
plexes made at 20 times equivalence.
For sucrose density gradient analysis, the 0.2-ml
samples of the above reaction mixtures were layered
on a 10 to 40% linear sucrose density gradient in VBS
and centrifuged in an ultracentrifuge (Spinco, model
L2) with an SW-SO rotor at 35,000 rpm for 24 hr at
4°C. Fractions collected drop-wise through a hole in
the bottom of the tube were counted for radio-
activity. The markers employed were human IgG
(6.8S), human 1gM (19S), human serum albumin
(HSA) (4.2S), and catalase (11.2S). IgG, 1gM, and
HSA were measured in the fractions by radial im-
munodiffusion, and catalase was measured by the dis-
appearance of peroxide as measured spectrophoto-
metrically at 240 mU.
A nalysis of Clq binding complexes isolated by su-
crose gradient analysis. Corresponding fractions ob-
tained by repeated sucrose gradient analyses on a
single serum specimen were pooled, dialyzed at 4°C
against a 0.05 M ammonium formate buffer, pH 7.4,
lyophilized, and stored at —70°C until used. By this
method, the complexes binding 125 I-Clq contained in
1.2 to 1.5 ml of serum could be isolated. For analysis,
the lyophilized pooled fractions were restored to a
volume of 0.5 ml with neutral phosphate buffered
saline and dialyzed against 0.2 M glycine buffer, pH
3.2. All fractions were tested for the presence of IgG
by double diffusion or by radial immunodiffusion
using monospecific antiserum to human IgG. In addi-
tion, by the same methods, the pooled fractions con-
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taming complexes were tested for the presence of Clq,
C3, C4, C5, properdin, factor B, and for 1gM and
IgA. The protein concentration of the pooled frac-
tions containing complexes was 1 to 2 mg/mi.
Measurement of complement components. Serum
complement components were measured by radial
immunodiffusion using monospecific antiserum as
described previously [11]. Antiserum to C2 was pre-
pared by immunization of a goat with a commercial
preparation of human C2 (Cordia Laboratories,
Miami, FA) incorporated in a complete Freund's
adjuvant. The antiserum was rendered monospecific
for C2 by absorption with normal human serum de-
pleted of C2 by heating to 56°C for 60 mm.
Immunohistologic studies. Renal biopsies of twelve
of the patients with MPGN, obtained within six
months of the serum specimen analyzed for com-
plexes, were available. For use in immunnohistologic
studies of the biopsy specimens, antibody was ren-
dered monospecific by the methods used previously
[11] and labeled by the method of Kawamura [121.
The method of preparation of sections for study was
previously described [13].
Results
Serum Clq-BA. The Clq-BA, representing the frac-
tion of added 125 i-Clq precipitated by 2.5% poly-
ethylene glycol (PEG), of 44 serum specimens from
normal subjects averaged 16% with a range of 7.4%
(2 SD). As shown in Figure 1, Clq-BA above this
range was observed in serum specimens from 10 of 20
patients with MPGN. Five with high Clq-BA had
Type I disease, two had Type II, and three had renal
transplantation as the result of renal failure due to
previous Type II disease. Two of the three patients
with renal transplants whose serum had high Clq-BA
had recurrence of the original disease. Four of the
heated serum specimens from the patients with
MPGN with high Clq-BA were subjected to ultra-
centrifugation at >< 150,000 g for 60 mm, conditions
which would remove immunoglobulin agregates from
the supernatant. The supernatants showed no signifi-
cant loss of Clq-BA, indicating that aggregates were
not responsible for the binding activity.
As also shown in Figure 1, serum specimens from
17 of 21 patients with SLE and 15 of 20 with AGN
also had increased Clq-BA.
Detection of Clq binding complexes by sucrose
gradient ultracentrifugation analysis. Sucrose density
gradient analysis of isolated 125 I-Clq added to buffer
revealed a single peak of radioactivity with a sedi-
mentation constant of 11.1S (Fig. 2, upper left). The
peak corresponded in position to that of catalase
(ll.2S). An identical peak was observed on analysis
of normal serum which had been incubated with 125
CIq (Fig. 2, lower left). In addition, with normal
serum, between 0.2 and 1% of the added 125 I-Clq was
found in the most heavily sedimenting fraction. This
could represent aggregated 125 I-Clq not removed by
the preliminary centrifugation.
Sucrose density gradient analysis of normal human
serum, to which had been added human lgG-anti IgG
complexes made at 20x antigen excess, gave a sharp
peak representing 125 I-Clq binding to material with a
sedimentation coefficient of 12.6S, as well as peaks
representing heavily sedimenting material and un-
bound Clq. The sedimentation coefficient of the Clq
binding material was not affected by variations in the
concentrations of the added complexes over a range
of 500 to 2000tg/ml.
Sucrose density gradient analysis of serum from
patients with MPGN after incubation with 125 I-Clq
often showed three peaks of radioactivity, one in the
l1.lS region representing unbound 125 I-Clq, one in
the 13.8 to 19.5S region representing complexes bind-
ing 125 I-Clq, and one in the most heavily sedimenting
fraction also seen with normal serum. The patterns
for two serum specimens which showed a high per-
centage of 125 I-Clq binding in the 13.8 to 19S region
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Fig. I. Clq-BA of serum specimens from normal subjects and patients
with membranoproliferative glomerulonephritis (MPGN), systemic
lupus erythemalosus (SLE), and acute poststreptococcal
glomerulonephritis (A GN).
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Fig. 2. Radioactivity (scale to the left) of fractions obtained by sucrose density gradient
analysis of normal serum, buffer, and serum from patients with various kinds of nephritis after
incubation with '2'I-Clq. Sedimentation coefficients were calculated using the scale to the
right.
are shown in the center of Figure 2. One specimen,
from a patient with Type I MPGN, contained com-
plexes with a sedimentation coefficient of 14.lS and
the other, from a patient with Type II MPGN, a
coefficient of 16.2S. As also noted in Figure 2, similar
patterns could be observed on analysis of serum from
patients with SLE and AGN. The complexes in the
serum of a patient with SLE had a sedimentation
coefficient of 17.8S and that in the serum of a patient
with AGN, 17.2S. When serum from a patient with
SLE was diluted 1:4 with buffer, the sedimentation
coefficient of the complexes was the same as that in
the undiluted serum.
In toto, peaks representing complexes in the 13.8 to
19.5S range were observed on sucrose density
gradient ultracentrifugation in serum specimens from
seven patients with SLE, from six with AGN, and
from five with MPGN. None of these patients had
had renal transplants. The actual sedimentation
coefficients observed are shown in Table 1. Of these
specimens, 17 showed a single peak in the 13.8 to
19.5S range, as in the representative patterns shown
in Fig. 2. However, the serum of patient 18, with
MPGN Type II, showed a main peak of 13.8S and a
contiguous smaller peak at 16.2S. It is apparent from
the data in Table 1 that the sedimentation coefficients
of the CIq binding complexes were in approximately
the same range in all the diseases studied.
All specimens in which Clq binding complexes
could be demonstrated by gradient analysis also had
increased Clq-BA, but in a number of specimens
showing increased CIq-BA, no peak of Clq binding
complexes was detectable by gradient analysis.
Composition of immune complexes isolated by su-
crose density ultracentrifugation. Corresponding frac-
tions obtained from repeated sucrose density gradient
ultracentrifugation analyses of a single serum speci-
men were pooled, dialyzed, and acidified, and the
presence of IgG sought in the poois by radial im-
munodiffusion and double diffusion using mon-
ospecific antibody. IgG was found only in pools rep-
resenting material sedimenting at 7S and in those
representing Clq binding complexes in the 13.8 to
19.5S region. IgG was not detectable in pools repre-
senting material with other sedimentation character-
istics.
Buffer MPGNType I
gM Catalase HSA
S LE
gM Catalase HSA
I I IgG1
MPGN Type II
—24
-20
—16
—12
—8
—4
1
305 10 15 20 25 30 0 5 10 15 20 25 30
Fraction number Fraction number
0 5 10 15 20 25
Fraction number
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Using radial immunodiffusion and double diffu-
sion, the presence of 1gM, IgA, Clq, C4, C5, proper-
din, and factor B, and the A determinant of the C3
was sought in the Clq binding complexes obtained
from pools derived from serum specimens from five
patients with MPGN, five with SLE, and three with
AGN. Clq, derived from the added 125 I-Clq, was
detectable in all. C5 and factor B were not found; the
antigenic determinants of these proteins would have
been destroyed by the prior heating of the serum.
Heating likewise reduces the ability of properdin to
react with antibody; it was present in the pools from
seven serum specimens and absent in six. The fre-
quency of the other proteins is shown in Table 1. All
pools of Clq binding complexes contained C3 and,
with the exception of one from a patient with AGN,
they all contained IgG and C4. 1gM was present in
easily detectable amounts in the complexes from two
patients with SLE and in all of those with AGN.
There was no correlation between the composition of
the complexes and their sedimentation velocities.
The data contained in Table 1 also allows corn-
parison of the composition of the complexes and the
protein deposited in the glornerulus in the patients
with MPGN. IgG and C3 were constituents of both
the glomerular deposits and the complexes in every
case. However, there was no correlation between the
composition of the complexes with respect to IgA
and 1gM and the presence of these proteins in the
glomeruli. For all the patients with MPGN, com-
parison was also made between the glornerular im-
rnunohistology and the presence of increased Clq-BA
in serum specimens obtained within six months of the
biopsy. Although the amount of glornerular immuno-
globulin deposition tended to be slightly greater in
patients with increased Clq-BA, the difference was
not striking nor statistically significant.
Correlations between Clq-BA and the clinical status
of patients with MPGN. Table 2 provides data allow-
ing correlation between the clinical status of the
patients with MPGN and the Clq-BA of their serum.
Specimens from five patients with Type I, and four
with Type II MPGN showed normal levels of Clq
binding activity. Of these nine patients, seven had
Table 1. Sedimentation coefficients and composition of circulating complexes in the serum of patients with MPGN,
for patients with MPGN, glomerular immunohistology of recent biopsy is also recorded
SLE and AGN;
Patient
number
S rate,
Clqbinding
material lgG IgA 1gM C3 C4
10
11
14
Clq binding materials
Immunohistology" (+l.5)c
Clq binding material
lmmunohistology(+l.5)
Clq binding material
Immunohistology (0)
MPGN Type I
17.6 +
1
14.1 +
2
18.7 +
2
0
1
0
0
0
1
0
1
0
0
tr
0
+
2
+
2
+
2
+
ND
+
ND
+
ND
12
16
Clq binding material
lmmunohistology(—l.5)
Clq binding material
lmmunohistology(+6)
MPGN Type II
13.8 +
2
16.2 +
1
0
0
0
1
0
2
0
3
+
1
+
1
+
ND
+
ND
17
18
19
20
21
22
23
Clq binding material
Clq binding material
Clq binding material
Clq binding material
Clq binding material
Clq binding material
Clq binding material
SLE
13.8 +
17.7 +
16.5 +
14.6 +
14.8 +
17.8 ND
19.5 ND
0
0
0
0
0
ND
ND
0
+
+
0
0
ND
ND
+
+
+
+
+
ND
ND
+
+
+
+
+
ND
ND
24
25
26
27
28
29
Clq binding material
Clq binding material
Clq binding material
Clqbindingmaterial
Clqbindingmaterial
Clqbindingmaterial
A GN
17.2 +
16.6 +
16.0 0
19.5 ND
17.6 ND
16.0 ND
0
0
0
ND
ND
ND
+
+
+
ND
ND
ND
+
+
+
ND
ND
ND
+
+
0
ND
ND
ND
+ indicates protein detected in Clq binding material;
b lmmunohistology graded, in order of intensity of fluorescence, 0, 1+, 2+, and 3+.
Figures in parentheses indicate time of serum minus time of biopsy in months.
0, protein not detected; tr, trace; ND, not done.
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Table 2. Correlations between serum Clq-BA, complement profile, and clinical status of patients with MPGN0
Serum
Serum Clq, Serum albumin
C4,andC2 C3 concen-
Patient Type of Clq-BA concen- concen- tration Renal
No. MPGN % trationb tration gm/IOOml function Remarks
1 I 20
Patients with normal Clq binding activity
N 3.9 N Clinically stable
2 1 13 N 1 4.8 N Clinically stable
3 1 15 N 3.9 N Clinically stable
4 1 20 N 1 4.3 N Clinically stable
5 II 18 N 1 4.3 N Clinically stable
6 11 11 N 1 4.2 N Clinically stable
7 II 19 N 3.4 N Clinically stable
8 I 12 N 4.1 N Recent onset; proteinuria 0.3 g/24 hr
9 Il 19 N N 4.3 N Recent onset; proteinuria 0.9 g/24 hr
10 1 58
Patients with increased Clq binding activity
N N 2.7 jfl Rapidly progressive disease
II I 85 3.8 UI Slowly progressing to end-stage
12 II 85 N <3.2 j Progressive disease
13 1 26 2.1 1 Recent onset
14 1 25 N 2.8 Recent onset
15 1 26 N N 3.8 N Clinically stable
16 II 42 N N 3.8 N Clinically stable
° None of the patients had had renal transplants.
Arrows indicate reduction in level of one or more of first three reacting components.
had their disease for a number of years, but from a
clinical standpoint, were judged to be stable at the
time the specimens were obtained; renal function was
normal, and hematuria, hypertension, and nephrotic
syndrome were not present. In the other two patients
in this group, the disease had first been manifest
within five months of obtaining the serum sepci-
ments. The disease in these two patients was not
severe in that renal function was normal and protein-
uria was slight.
Of the seven patients with increased Clq-BA, five
had evidence of active disease. Patients 10, 11, and 12
had long-standing disease and prior to, and since,
obtaining the serum specimen have had progressive
deterioration of renal function. Patients 13 and 14
with slightly increased Clq binding activity had dis-
ease of recent onset characterized by nephrotic syn-
drome and mild renal failure. The remaining two
patients in this group were judged to be clinically
stable.
Correlations between Clq-BA and complement pro-
file in patients with MPGN. Data correlating the com-
plement profile with the Clq-BA are also shown in
Table 2. Among nine specimens with normal Clq-BA,
none had reduced levels of the first three reacting
components of complement, whereas of seven speci-
mens with increased Clq-BA, four had reduced levels
of these components. In two of these specimens
(patients 11 and 13), levels of all of the first three
reacting components, as well as of C3 and properdin,
were reduced. The incidence of reduced C3 levels was
higher in those with normal Clq-BA. Reduced levels
of properdin and factor B, not shown, were equally
distributed among specimens from both groups.
There was no correlation between the percent of
binding activity and the serum complement levels.
Discussion
Methods for the detection of circulating immune
complexes, depending on their ability to bind Clq, are
potentially subject to error since DNA and bacterial
lipopolysaccharides also have this property. The ef-
fect of these substances, added to serum, on Clq-BA
has been tested by Nydegger et a! [3] and by Zubler et
al [4]. By the method used in the present study [3],
Clq-BA was increased by 5% when sDNA was added
to serum in a concentration of 25tg/ml. Addition of
nDNA had no effect. Using the modified Clq binding
test [4], sDNA at a concentration of 6tg/ml in-
creased Clq-BA by 12% and nDNA at 3sg/ml, by
4%. At higher concentrations, Clq-BA fell. These
DNA concentrations are of the magnitude found at
various times in the serum of patients with lupus [14]
and in the present study, slight overestimation of the
Clq-BA in the specimens from patients with SLE as a
result of free DNA cannot be ruled out. Addition of
several bacterial lipopolysaccharides to serum in con-
centrations up to 500tg/ml was found to have no
affect on Clq-BA [4]. It should be noted that the Clq
binding material, isolated by sucrose gradient ultra-
centrifugation in the present study, contained in ev-
ery case immunoglobulins and complement corn-
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ponents, giving evidence that immune complexes
were present. IgG was absent in all other fractions
except those containing 7S protein. In the specimens
from patients with SLE, DNA could have been pres-
ent in this Clq binding material as an antigen [15].
The sensitivity of tests depending on Clq binding to
detect immune complexes are usually compared in
terms of the minimal concentration of the aggregated
IgG they can detect. Comparison on this basis is,
however, difficult since Clq binding to aggregates
depends on the size of the aggregates [4] which is
usually not reported. In the method employed here,
the lower limit of detection was determined to be an
aggregate concentration of approximately 1 0zg/ml
[3]. Greater sensitivity is claimed for other tests re-
cently described [161. Using serum from patients with
SLE, the results of the modified Clq binding tests
have been found by others [17] to correlate well with
measurement of complexes by a method depending
on inhibition of uptake of radiolabeled aggregated
IgG by guinea pig peritoneal macrophage cells [18].
The modified Clq binding test used in this com-
parison, however, has greater sensitivity for the de-
tection of complexes in SLE serum than the unmodi-
fied test employed in the present study [4].
Apparently, heating of the serum, as used in the
unmodified test, reduces the ability of SLE complexes
to bind Clq; greater Clq binding was observed in the
presence of (EDTA), as used in the modified test.
The composition of circulating complexes isolated
by sucrose gradient ultracentrifugation using bound
Clq as a marker, as carried out in the present study,
has not been previously reported, and comparison
can be made only with that of circulating cryoglobu-
lins, thought to be the in vitro representation of im-
mune complexes circulating in vivo. The composition
of cryoprecipitates isolated from the serum of
patients with acute and chronic glomerulonephritis,
as reported by various authors [19—21], is widely
variable. As in the binding material isolated in the
present study, IgG is almost always detectable in the
cryoprecipitate. C3, consistently observed in the pres-
ent study, has been reported by one group to be
always present in cryoprecipitates [21], but other
observers [19, 20] found it to be frequently undetec-
table. The reports also differ with respect to the fre-
quency with which 1gM is detectable. IgA, tested for
in one study [20], was, as in the present study, rarely
found.
Correlations between the composition of the gb-
merular immune deposits and of the circulating com-
plexes in the patients with MPGN indicated that both
contained IgG and C3, but the deposits frequently
obtained 1gM and IgA which was absent in Clq bind-
ing material. Similar discrepancies have been ob-
served between the composition of glomerular depos-
its and circulating crygbobulins [19, 20]. Whether this
discrepancy is the result of greater sensitivity of im-
munofluorescence in detecting these proteins or to
other factors could not be determined.
In the three types of glomerulonephritis studied,
the sedimentation coefficients of the complexes were
in the same range, i.e., 13 to 19S. The method did not
allow delineation of complexes greater than 19S, and
the presence of these cannot be ruled out. On the
other hand, an abundance of complexes sedimenting
at greater than 19S would not be predicted since the
amount of 1251-Clq in the heavily sedimenting fraction
was no greater in the specimens from patients with
gbomerubonephritis than in specimens from normal
subjects. The sedimentation coefficients fell into the
range observed by Germuth and Rodriquez [22] for
complexes in the serum of rabbits with chronic serum
sickness produced by repeated injections of BSA.
They observed that rabbits which had low level an-
tibody response to BSA produced complexes sedi-
menting over a range intermediate between BSA and
1gM, with coefficients averaging approximately 15S
(Class I complexes). These animals exhibited lesions
in the gbomerular capillary loops; electron micro-
scopy revealed subepithelial deposits. In contrast,
rabbits with a somewhat greater response to BSA had
complexes in the l9S range (Class II complexes), and
by electron microscopy, deposits were found in the
mesangium. It should be pointed out that the sedi-
mentation rates cited for the animal models represent
mean values, and that the complexes actually
spanned a range of S rates so that the two groups to
some extent overlapped. In the present study, the size
of the complexes conforms to the range for Class I
complexes and extends into the Class II range of the
BSA model. In all of the three diseases studied, gb-
merular morphology is characterized by both mesan-
gial and capillary wall involvement, and similar
ranges in S rates of the complexes might therefore be
expected. It is relevant to point out that in the animal
models, corticosteroids exert a modifying effect; un-
der their influence, Class I complexes can localize in
sites normally characteristic of Class H complexes
[221. The patients with MPGN and SLE were being
treated with steroids, and the data should therefore
be interpreted with this in mind,
Increased Clq-BA, as well as Clq binding com-
plexes, detectable by sucrose gradient ultracentrifu-
gation were found in the present study with the same
frequency in serum from patients with Type II
MPGN as in those with Type I. The observations
suggest that these two types of MPGN share a corn-
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mon pathogenesis, but they shed no light on the
factors responsible for their differences. The correla-
tions between increased Clq binding activity and the
clinical status of the patient suggests that the material
binding Clq was nephritogenic. Most of the patients
without nephrotic syndrome or renal failure whose
glomerulonephritis was judged to be clinically stable
had normal Clq-BA. In contrast, patients with renal
failure and, usually, a nephrotic syndrome, several of
whom had progressive disease, had increased Clq-
BA. The significance of the observation that two
patients who were clinically stable also had increased
Clq-BA cannot be judged from the present data and
will require measurement of complexes in serial speci-
mens for its elucidation.
Comparison of complement levels and Clq-BA in the
serum of patients with MPGN indicates that binding
activity can be present without abnormalities in se-
rum complement levels, and conversely, the C3 levels
may be low in the presence of normal binding activ-
ity. Of seven serum specimens with elevated Clq-BA,
only four had reduced levels of one or more of the
first three reacting components. In this disease, there-
fore, the levels of these components appear to be a
poor indicator of the presence of complexes. In lupus
nephritis, a good correlation was observed between
C4 levels and the Clq-BA, but a poor correlation was
observed with Clq, C3, and total complement levels,
especially at low or intermediate levels of Clq-BA [4].
The poor correlation of Clq-BA with C3 levels in the
present study may have been the result of diminished
synthesis of C3 (23—25) or to C3 breakdown by
amounts of nephritic factor undetectable by the
method employed.
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